REMAP-CAP’S NEW TRIAL DEVELOPMENTS
The world of REMAP-CAP is constantly evolving, here’s what’s new!
REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.
REMAP-CAP: NEW RESULTS FROM THE ACE2 RAS DOMAIN!
New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.
REMAP-CAP reaches new milestone
REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.
Spiral joins first of its kind clinical trial - continuing the fight against COVID
Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for critical care patients.
Full-dose blood thinners benefit moderately ill COVID-19 patients
REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 - a recently published report discusses a trial that employed #REMAP-CAP as one of its three collaborating platforms.
Covid-19, the world’s most complex clinical trial, and the small New Zealand company who made it possible
A small software company in New Zealand, Spiral, helped to create a ground-breaking clinical trial in unprecedented timeframes. One that had a real, human benefit for COVID-19 sufferers around the world.
